Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell LymphomaMichael Wang, Nirav N. Shah, Benoît Tessoulin et al.|Journal of Clinical Oncology|2023Cited by 106
Characteristics and Prognosis Factors of Pneumocystis jirovecii Pneumonia According to Underlying DiseaseRomain Lécuyer, Nahéma Issa, Fabrice Camou et al.|CHEST Journal|2024Cited by 49
Epidemiology and Clinical Impact of Respiratory Coinfections at Diagnosis of <i>Pneumocystis jirovecii</i> PneumoniaRomain Lécuyer, Nahéma Issa, Benoît Tessoulin et al.|The Journal of Infectious Diseases|2021Cited by 36
Respiratory management of critically ill pneumocystis pneumonia patients: a multicenter retrospective studyFlorian Reizine, Noémie Coron, Romain Lécuyer et al.|Annals of Intensive Care|2025Cited by 4
Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R/R marginal zone lymphoma: phase 1/2 BRUIN studyKrish Patel, P. L. Zinzani, Julie M Vose et al.|Blood Advances|2026Cited by 1